The firm is a privately held life sciences investment vehicle focused on funding clinical development in exchange for equity and warrants. The firm primarily invests in publicly traded companies and structures investments to directly support clinical trials and related services. Typical allocations range from approximately $2M to $6M, with the ability to deploy additional capital through tranche financings. The firm focuses on companies conducting clinical trials in the United States.
The firm is active across therapeutics, diagnostics, and medical devices and is generally agnostic to technology type and disease indication. The firm is particularly interested in companies that are entering or currently in proof-of-concept clinical trials, typically at Phase Ib or Phase IIa stages.
From a company and management team perspective, the firm seeks publicly traded companies with experienced leadership teams and actively engaged boards of directors. The firm is open to both leading and co-investing. While the firm primarily invests in public companies, it remains open to engaging early with emerging clinical-stage opportunities ahead of formal investment readiness.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment